ClinicalTrials.gg
RecruitingNCT07846007PD GPi-TUSUpdated Sep 29, 2026

Effects of Excitatory and Inhibitory LIFUS of GPi in Parkinsonian Patients Without DBS

An interventional study of LIFUS: Active 5 Hz Theta Burst and LIFUS: Active 10 Hz in Parkinson Disease (PD), sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Feb 2024, registered Feb 2026).
  • Started Feb 2024; still recruiting 2 years 9 months later.
Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Parkinson Disease by University Health Network, Toronto — 5 open to participants now, 6 under way, none of them phase 3. Parkinson Disease · University Health Network, Toronto.

Planned enrollment
8th of 13
15 · median 17
Started
2024
the only one that year
No phase
8 of 17
4 open now
Registered
17th of 17
by date

Among the 17 studies in Parkinson Disease by University Health Network, Toronto, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 8 with no phase, and was the 17th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 17 studies in Parkinson Disease by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Parkinson Disease by University Health Network, Toronto, or all of them as a file.
02

Study summary

Low intensity focused ultrasound (LIFUS) is a novel non-invasive brain stimulation (NIBS) technique that permits stimulation with high spatial focality and can reach greater depth compared other methods. This study will look at the effects of two different LIFUS stimulations on task performance in patients with Parkinson's disease. The effects of real stimulation will also be compared to sham stimulation. The evaluations will include behavioral tasks on the computer, the Unified Parkinson's Disease Rating Scale (UPDRS) motor scoring, and finger accelerometry recordings. These will be done before the LIFUS simulations and repeated after. This is to evaluate the different mechanisms and efficacy of these stimulations on deep brain areas.

Read the detailed description

The goal of this study is to evaluate the effects of two different deep brain LIFUS protocols on task performance in PD patients. We will use two different protocols (5 Hz theta Burst vs 10 Hz inhibitory), bilaterally on the GPi of PD patients in two different sessions and evaluate their performance in visuomotor tasks using stop signal paradigm. We will also use active sham in a separate session bilaterally on the occipital cortex, more specifically Brodmann area 19 to compare differences in tremor activity. We will record behavioral performance of the patients to disentangle effects of different TUS protocols on PD patients. We will also use finger accelerometer on the tremor dominant hand, to evaluate possible changes in tremor.

For each participant, there will be four visits. In the first visit, a structural MRI scan will be obtained. In the subsequent three visits, the LIFUS experiments including the behavioral tasks on the computer, UPDRS motor scoring, and finger accelerometry recordings will be conducted in random order. In these visits, the task performance (stop-signal task) will be recorded before and after applying the 3 different LIFUS paradigms: 1) theta burst TUS of the GPi in one session, 2) 10Hz TUS of the GPi in one session, and 3) active sham condition in the occipital cortex (bilateral) where we will use theta burst LIFUS to the Brodmann area 19 at a TPO distance of \~30mm. Visits 2, 3, and 4 will be separated by at least 1 week each and theta burst TUS (2 minutes x2 =4 min), 10 Hz protocol (Burst length 30ms, period 1000, 30% dc. Total Time: 40 seconds x2= 80 seconds) and sham theta bust TUS will be tested in random order.

03

Conditions studied

  • Parkinson Disease (PD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-90 years of age
  • Confirmed diagnosis of Parkinson's disease
  • Stable dopaminergic medication dose for a minimum of 4 weeks

Exclusion criteria

Exclusion Criteria:

  • History of stroke or seizure
  • Comorbid dementia
  • Scored below 22 on the (MoCA)
  • Has intracranial implant(s) or device(s)
  • Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)
  • Has a previous surgical intervention to treat the movement disorder such as lesioning or a Deep Brain Stimulation system in place.
  • Presence of metal implanted in body that is in TMS/MRI/peripheral electrical stimulation
  • Pregnancy
  • Major depression/psychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study
  • Is on antipsychotics, anti-depressants, marijuana, or other recreational drugs that affect the nervous system
  • Major musculoskeletal or neuromuscular disease or disorder of the hands, wrists and limbs
  • Severe Dyskinesia
  • Major systemic illness or infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Low Intensity Focused Ultrasound

    3 different LIFUS paradigms in random order: 1) theta burst TUS of the GPi in one session, 2) 10Hz TUS of the GPi in one session, and 3) active sham condition in the occipital cortex (bilateral) where we will use theta burst LIFUS to the Brodmann area 19 at a TPO distance of \~30mm.

    Device: LIFUS: Active 5 Hz Theta Burst · Device: LIFUS: Active 10 Hz · Device: LIFUS: Sham

Interventions

  • DeviceLIFUS: Active 5 Hz Theta Burst

    LIFUS 5 Hz theta burst bilaterally on the GPi

  • DeviceLIFUS: Active 10 Hz

    LIFUS 10 Hz bilaterally on the GPi

  • DeviceLIFUS: Sham

    Sham: LIFUS theta burst to occipital lobe

06

What researchers measure

Primary outcomes

  1. Stop-Signal Task

    Time frame: Visits 2-4: before stimulation, 20 minutes post round 1 of stimulation, and 25 minutes post round 2 of stimulation

Secondary outcomes

  1. Unified Parkinsons Disease Rating Scale (UPDRS)

    Part III - Motor Assessment

    Time frame: Visits 2-4: At the beginning of the visit, and at the end of the visit after all stimulation. Visits 2-4 will take place over at least 3 weeks as each visit is at least 1 week apart.

  2. Rest Tremor

    Resting tremor will be measured by an accelerometer

    Time frame: Visits 2-4: resting tremor will be recorded by an accelerometer periodically during each visit. This will be over at least 3 weeks, since each visit is at least 1 week apart.

  3. Postural Tremor

    Postural tremor will be measured as arms are outstretched using an accelerometer

    Time frame: Visit 2 - 4. At each visit, it will be recorded twice. Once before the stimulation and another after. This will take place over at least 3 weeks, since each visit is at least 1 week apart.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2027, 46 months after the start.

Of 1,295 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 46 months is above that.

Counting every sponsor, half of 1,371 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2026
First posted
Sep 29, 2026
StartActual
Feb 14, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846007
Responsible party
Robert Chen (Senior Scientist, University Health Network, Toronto) — Principal investigator
First posted
Sep 29, 2026
Start date
Feb 14, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Julian Kwok
Contact
julian.kwok@uhn.ca
416-603-5800 ext. 2708
Regina Annirood
Contact
regina.annirood@uhn.ca
Robert Chen, MBBS
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion